. Author manuscript; available in PMC: 2017 Jun 9.

Published in final edited form as: Neuroepidemiology. 2016 Jan 31;47(3-4):192–200. doi: 10.1159/000450855

Table 3.

Adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between caffeinated coffee consumption and Parkinson’s disease in the PEGASUS and PASIDA studies, by ADORA2A and CYP1A2 genotypes: meta-analytic results using random-effect models

Caffeinated coffee	Homozygous Major		Heterozygous		Homozygous Minor
Caffeinated coffee	OR^a	95% CI	OR^a	95% CI	OR^a	95% CI
ADORA2A rs5751876 in PEGASUS (LD with rs5760423 in PASIDA)
Cups/day, mean ± SD	0.97	0.91–1.03	0.96	0.90–1.02	0.77	0.51–1.16
Ever vs Never^*	0.85	0.53–1.36	0.66	0.51–0.84	0.65	0.43–0.98
CYP1A2 rs762551
Cups/day, mean ± SD	0.94	0.82–1.09	0.94	0.88–1.00	0.86	0.69–1.08
Ever vs Never^*	0.70	0.55–0.89	0.83	0.64–1.08	0.43	0.17–1.10
CYP1A2 rs2472304
Cups/day, mean ± SD	0.99	0.93–1.04	0.88	0.72–1.08	0.84	0.71–0.99
Ever vs Never^*	0.75	0.58–0.95	0.71	0.55–0.91	0.67	0.30–1.48

Heavy vs light coffee consumption in the PASIDA study

OR^a: Adjusted for age, sex and site in PEGASUS; adjusted for the covariates year of birth, gender and onset/index age (continuous) in PASIDA